Scientist.com, recognized as a leading AI driven platform for coordinating R&D activities across the life sciences sector, has officially completed its acquisition by GHO Capital Partners LLP. GHO is a global healthcare focused private equity firm, and this deal marks the beginning of a new phase of rapid growth for Scientist.com. The company plans to strengthen its core mission of improving how pharmaceutical research is managed by simplifying and supporting every stage of external research projects, from early planning to final delivery.
Health Technology Insights: Daiichi Sankyo Begins Trial for STING Agonist ADC DS-3610
Kevin Lustig, CEO, and Chris Petersen, CTO, who cofounded Scientist.com, described the moment as a major milestone for both the company and the worldwide scientific community that relies on it. Lustig and Petersen said that teaming up with GHO gives them a partner that fully understands their long term vision and has extensive experience helping health technology businesses scale. With GHO’s backing, the company intends to increase investment in its AI enabled orchestration system and broaden its global reach. They noted that this partnership places them in a stronger position to meet rising demand for faster, more intelligent, and better regulated research operations.
Health Technology Insights: Freenome Names Rob Guigley CCO as Exact Sciences Deal Clears
Since launching in 2007, Scientist.com has grown from being an early marketplace for outsourced scientific services into a comprehensive platform that helps pharmaceutical and biotech organizations manage complex research workflows. The system connects clients with a network of more than six thousand carefully reviewed suppliers of scientific tools and services. By digitizing the full outsourced R&D process, the platform supports everything from selecting the right provider and drafting contracts to ensuring compliance and tracking budgets. This approach helps research organizations shorten timelines, lower operational risk, and make better decisions.
Now that the acquisition is complete, both parties have outlined shared priorities. Scientist.com and GHO plan to increase adoption across Europe and other regions while accelerating development of advanced AI features. These upgrades include smarter vendor management tools, automated processes for contracting, and predictive systems that help teams plan and execute research projects more effectively.
Edward de Nor and Stuart Quin, partners at GHO Capital, said they are excited to finalize the investment. They praised Scientist.com as an early mover in bringing together AI, digital marketplaces, and modernized supply chains for the biopharmaceutical industry. According to them, their goal is to support the company’s ambition to make outsourced R&D more efficient and more accessible. They emphasized that this merger can help achieve meaningful improvements in the speed and quality of scientific innovation, benefiting healthcare worldwide.
GHO Capital Partners oversees more than ten billion dollars in assets and focuses exclusively on growing companies in the healthcare space. The firm’s strategy is built around supporting high growth areas such as biopharmaceutical services, health technology, and tools for the life sciences sector. The partnership with Scientist.com aligns closely with this focus and sets the stage for significant advancement in the coordination and execution of global research operations.
Health Technology Insights: MY DR NOW Opens New Clinic at 24th Street and Baseline
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
